abaloparatide CAS NO.247062-33-5

Shanghai Yaxian Chemical Co.,Ltd is a well-known technology-based company specialized in synthetic custom peptides, custom antibodies, as well as active pharmaceutical ingredients (APIs). 

With a 500 square meters plant and office space based in Jiangsu, there are total 3 workshops with 2 chemical synthesis lines, 2 peptide synthesis lines and 1 R&D center.

Our experts have more than 15 years of experience in peptide research. Yaxian is also well-equipped with the latest state-of-the peptide synthesis equipment and technology to provide reliable products and services to our global clients.

Abaloparatide is an analog of PTHrP (parathyroid hormone-related protein). It was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a synthetic peptide that is related to hPTHrP and has demonstrated in preclinical testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization.